Janssen Research and Development, LLC (Janssen), in collaboration with SDSC and the Scripps Translational Science Institute (STSI), recently launched a project to conduct whole-genome sequencing of 438 patients with rheumatoid arthritis to better understand the disease, as well as explore genetic factors of patient response to a biologic therapy discovered, developed, and currently marketed by Janssen in the United States.  The analysis began with 50 terabytes of “read” data generated by DNA sequencers from samples originally obtained from each of the study participants. These source data were fed into a 14-step processing “pipeline” using open source software tools. Key components of the analysis were mapping the DNA read sequences from each patient against a reference genome and calling to identify the variants between the t To read further, please visit http://www.sdsc.edu/News%20Items/PR031914_janssen.html.